ImClone Systems

ImClone requests expanded Erbitux label

ibtimes.com     yesterday   2 related          

ImClone Systems Inc. said Wednesday it has asked regulators to approve its drug Erbitux as a primary treatment for head and neck cancers. New York-based ImClone, which partners with Bristol-Myers Squibb Co. to market the...                    

comments

Zacks Analyst Interview Highlights: Genentech, ImClone Systems, Bristol-Myers Squibb and Celgene...

yahoo.com     Sep 2, 2008   2 related          

Tuesday September 2, 6:00 am ET CHICAGO--(BUSINESS WIRE)--Zacks.com releases the latest Analyst Interview. Today’s interview is with senior analyst Grant Zeng, who discusses Genentech (NYSE: Get the most recent insight...                    

comments

                   

Dako, Bristol-Myers combine forces on theranostics

pharmiweb.co.uk     Aug 27, 2008          

Dako (Glostrup, Denmark) has entered into a collaboration with Bristol-Myers Squibb Co. (BMS; New York City) to develop pharmacodiagnostic tests intended to identify patients more likely to benefit from treatment with...                    

comments

Bristol-Myers reaffirms 2008 guidance (AP)

yahoo.com     Aug 27, 2008   1 related          

Thursday May 29, 5:01 pm ET Bristol-Myers Squibb reaffirms 2008 outlook following buyout proposal for Kosan Biosciences NEW YORK (AP) -- Drug developer Bristol-Myers Squibb Co. reaffirmed its full-year profit guidance...                    

comments

                   

Randomized Phase 2 Study of IMC-A12 and IMC-1121B for Advanced Prostate Cancer Commences Patient...

earthtimes.org     Aug 26, 2008          

NEW YORK - ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that its disease-directed Phase 2 clinical trial in...                    

comments

theconservativevoice.com: The Conservative Voice theconservativevoice.com

King offers $1.4 billion in cash for Alpharma

wtop.com     Aug 22, 2008   14 related          

NEW YORK (AP) - Drugmaker King Pharmaceuticals Inc. said Friday it offered Alpharma Inc. $1.4 billion in cash as part of an unsolicited buyout bid in a move to create a large diverse specialty pharmaceutical company and...                    

comments

                   
theconservativevoice.com: The Conservative Voice theconservativevoice.com

King says Alpharma rebuffed a $1.4B buyout bid

theconservativevoice.com     Aug 22, 2008   15 related          

King says Alpharma rebuffed a $1.4B buyout bid King Pharmaceuticals Inc. said Friday that rival Alpharma Inc. has rejected a $1.4 billion buyout offer but indicated it is prepared to take the bid directly to shareholders...                    

comments

                   

Eli Lilly: Completes SGX Acquisition

redorbit.com     Aug 21, 2008   7 related          

Eli Lilly has completed its purchase of US biotechnology company SGX Pharmaceuticals for $64m. The acquisition is expected to compliment Lilly's pursuit of innovative R&D programs, and represents a further investment by a...                    

comments

PDL BioPharma shares rise on licensing deal

ibtimes.com     Aug 20, 2008   25 related          

NEW YORK - PDL BioPharma Inc.'s stock gained ground Wednesday after pharma giant Bristol-Myers Squibb Co. signed a deal to license the biotechnology company's developing blood cancer drug. Shares of Princeton, N.J.-based PDL...                    

comments

Biotech buyout action likely to continue

ibtimes.com     Aug 20, 2008   4 related          

NEW YORK - A buyout bull's-eye will likely remain on biotechnology companies over the next few years as major pharmaceutical companies continue taking advantage of a weak dollar and a surplus of cash to buy pipeline additions....                    

comments

1 2 3 4 5 next »